Novel anticoagulants in atrial fibrillation stroke prevention

Therapeutic Advances in Chronic Disease

Volumn 3, Issue 3, 2012, Pages 123-136

  Norgard, Nicholas ^a   Dinicolantonio, james ^b   Topping, Taylor ^c   Wee, Benjamin ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b Wegmans Pharmacy   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d KINGSBROOK JEWISH MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Apixaban; Dabigatran; Rivaroxaban; Thromboembolism; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BETRIXABAN; CYTOCHROME P450 INHIBITOR; DABIGATRAN; EDOXABAN; GLYCOPROTEIN P INHIBITOR; KETOCONAZOLE; RITONAVIR; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DYSPEPSIA; HEART ATRIUM FIBRILLATION; HEART PROTECTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

EID: 84868662971     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622312438934     Document Type: Review

References (88)

1. Aguilar M. Hart R. (2005) Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev CD001925.
2. Aithal G.P. Day C.P. Kesteven P.J. Daly A.K. (1999) Association of polymorphisms in the cytochrome P 450 Cyp2c9 with warfarin dose requirement and risk of bleeding complications. Lancet 353: 717–719.
3. Blech S. Ebner T. Ludwig-Schwellinger E. Stangier J. Roth W. (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36: 386–399.
4. Connolly S. Pogue J. Hart R. Pfeffer M. Hohnloser S. Chrolavicius S. et al. (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903–1912.
5. Connolly S.J. Eikelboom J. Joyner C. Diener H.-C. Hart R. Golitsyn S. et al. (2011) Apixaban in patients with atrial fibrillation. N Engl J Med, in press.
6. Connolly S.J. Ezekowitz M.D. Yusuf S. Eikelboom J. Oldgren J. Parekh A. et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139–1151.
7. Connolly S.J. Ezekowitz M.D. Yusuf S. Reilly P.A. Wallentin L. (2010) Newly identified events in the RE-LY trial. N Engl J Med 363: 1875–1876.
8. Connolly S.J. Laupacis A. Gent M. Roberts R.S. Cairns J.A. Joyner C. (1991) Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 18: 349–355.
9. Connolly S.J. Pogue J. Eikelboom J. Flaker G. Commerford P. Franzosi M.G. et al. (2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118: 2029–2037.
10. Couris R. Tataronis G. Mccloskey W. Oertel L. Dallal G. Dwyer J. et al. (2006) Dietary vitamin K variability affects international normalized ratio (INR) coagulation indices. Int J Vitam Nutr Res 76: 65–74.
11. de Assis M.C. Rabelo E.R. Avila C.W. Polanczyk C.A. Rohde L.E. (2009) Improved oral anticoagulation after a dietary vitamin K-guided strategy: a randomized controlled trial. Circulation 120: 1115-1122, 1113 p following 1122.
12. Diener H.-C. Connolly S.J. Ezekowitz M.D. Wallentin L. Reilly P.A. Yang S. et al. (2010) Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 9: 1157–1163.
13. Eerenberg E.S. Kamphuisen P.W. Sijpkens M.K. Meijers J.C. Buller H.R. Levi M. (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124: 1573–1579.
14. Eriksson B.I. Quinlan D.J. Weitz J.I. (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 48: 1–22.
15. Eriksson B.I. Smith H. Yasothan U. Kirkpatrick P. (2008) Dabigatran etexilate. Nat Rev Drug Discov 7: 557–558.
16. Ezekowitz M. (2010) A Randomized Clinical Trial of Three Doses of a Long-Acting Oral Direct Factor Xa Inhibitor Betrixaban in Patients with Atrial Fibrillation (Explore-Xa). Available at: http://www.cardiosource.org/Science-And-Quality/Clinical-Trials/E/EXPLOREXa.aspx. (accessed 21 October 2011).
17. Ezekowitz M.D. Bridgers S.L. James K.E. Carliner N.H. Colling C.L. Gornick C.C. et al. (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327: 1406–1412.
18. Ezekowitz M.D. Reilly P.A. Nehmiz G. Simmers T.A. Nagarakanti R. Parcham-Azad K. et al. (2007) Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (Petro Study). Am J Cardiol 100: 1419–1426.
19. Fang M.C. Stafford R.S. Ruskin J.N. Singer D.E. (2004) National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 164: 55–60.
20. Franco V. Polanczyk C.A. Clausell N. Rohde L.E. (2004) Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 116: 651–656.
21. Freeman J.V. Zhu R.P. Owens D.K. Garber A.M. Hutton D.W. Go A.S. et al. (2010) Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 154: 1–11.
22. Friberg J. Buch P. Scharling H. Gadsbphioll N. Jensen G.B. (2003) Rising rates of hospital admissions for atrial fibrillation. Epidemiology 14: 666–672.
23. Gage B.F. (2009) Can we rely on RE-LY? N Engl J Med 361: 1200–1202.
24. Gage B.F. Waterman A.D. Shannon W. Boechler M. Rich M.W. Radford M.J. (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285: 2864–2870.
25. Gladstone D.J. Bui E. Fang J. Laupacis A. Lindsay M.P. Tu J.V. et al. (2009) Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40: 235–240.
26. Go A.S. Hylek E.M. Chang Y. Phillips K.A. Henault L.E. Capra A.M. et al. (2003) Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290: 2685–2692.
27. Granger C.B. Alexander J.H. Mcmurray J.J. Lopes R.D. Hylek E.M. Hanna M. et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981–992.
28. Gurwitz J.H. Field T.S. Radford M.J. Harrold L.R. Becker R. Reed G. et al. (2007) The safety of warfarin therapy in the nursing home setting. Am J Med 120: 539–544.
29. Halabi A. Kubitza D. Zuehlsdorf M. Becka M. Mueck W. Maatouk H. (2007) Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban – an oral, direct factor Xa inhibitor. J Thromb Haemost 5: P-M-635.
30. Harper P.L. Pollock D. (2008) Anticoagulant self-management using near patient testing and decision support software provided via an internet website improved anticoagulant control in patients on long-term warfarin. ASH Annual Meeting Abstracts 112: 1278–.
31. Hart R.G. Pearce L.A. Aguilar M.I. (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146: 857–867.
32. Herman D. Peternel P. Stegnar M. Breskvar K. Dolzan V. (2006) The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 95: 782–787.
33. Higashi M.K. Veenstra D.L. Kondo L.M. Wittkowsky A.K. Srinouanprachanh S.L. Farin F.M. et al. (2002) Association between Cyp2c9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287: 1690–1698.
34. Holbrook A.M. Pereira J.A. Labiris R. Mcdonald H. Douketis J.D. Crowther M. et al. (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165: 1095–1106.
35. Jones M. Mcewan P. Morgan C.L. Peters J.R. Goodfellow J. Currie C.J. (2005) Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 91: 472–477.
36. Juurlink D.N. (2007) Drug interactions with warfarin: what clinicians need to know. CMAJ 177: 369–371.
37. Khan T. Wynne H. Wood P. Torrance A. Hankey C. Avery P. et al. (2004) Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 124: 348–354.
38. Kubitza D. Becka M. Mueck W. Halabi A. Maatouk H. Klause N. et al. (2010) Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 70: 703–712.
39. Kubitza D. Becka M. Roth A. Mueck W. (2008) Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 24: 2757–2765.
40. Kubitza D. Becka M. Wensing G. Voith B. Zuehlsdorf M. (2005) Safety, pharmacodynamics, and pharmacokinetics of Bay 59-7939--an oral, direct factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61: 873–880.
41. Kubitza D. Becka M. Zuehlsdorf M. Mueck W. (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (Bay 59-7939) in healthy subjects. J Clin Pharmacol 47: 218–226.
42. Kurnik D. Loebstein R. Rabinovitz H. Austerweil N. Halkin H. Almog S. (2004) Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients. A prospective, controlled trial. Thromb Haemost 92: 1018–1024.
43. Leung A.Y. Chow H.C. Kwong Y.L. Lie A.K. Fung A.T. Chow W.H. et al. (2001) Genetic polymorphism in exon 4 of cytochrome P 450 Cyp2c9 may be associated with warfarin sensitivity in Chinese patients. Blood 98: 2584–2587.
44. Liesenfeld K.H. Schafer H.G. Troconiz I.F. Tillmann C. Eriksson B.I. Stangier J. (2006) Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 62: 527–537.
45. Lin H.J. Wolf P.A. Kelly-Hayes M. Beiser A.S. Kase C.S. Benjamin E.J. et al. (1996) Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27: 1760–1764.
46. Mackman N. (2009) The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 108: 1447–1452.
47. Mant J. Hobbs F.D. Fletcher K. Roalfe A. Fitzmaurice D. Lip G.Y. et al. (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370: 493–503.
48. Marini C. de Santis F. Sacco S. Russo T. Olivieri L. Totaro R. et al. (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36: 1115–1119.
49. Matchar D.B. Samsa G.P. Cohen S.J. Oddone E.Z. Jurgelski A.E. (2002) Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med 113: 42–51.
50. Meckley L.M. Wittkowsky A.K. Rieder M.J. Rettie A.E. Veenstra D.L. (2008) An analysis of the relative effects of Vkorc 1 and Cyp2c9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 100: 229–239.
51. Miyasaka Y. Barnes M.E. Gersh B.J. Cha S.S. Bailey K.R. Abhayaratna W.P. et al. (2006) Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114: 119–125.
52. Nagarakanti R. Ezekowitz M.D. Oldgren J. Yang S. Chernick M. Aikens T.H. et al. (2011) Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 123: 131–136.
53. O'reilly R.A. Aggeler P.M. (1968) Studies on coumarin anticoagulant drugs. initiation of warfarin therapy without a loading dose. Circulation 38: 169–177.
54. Ogata K. Mendell-Harary J. Tachibana M. Masumoto H. Oguma T. Kojima M. et al. (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50: 743–753.
55. Oldgren J. Alings M. Darius H. Eikelboom J. Ezekowitz M. Parekh A. et al. (2010) Dabigatran etexilate versus warfarin in atrial fibrillation patients with low, moderate and high CHADS 2 score – a RE-LY subgroup analysis. J Am Coll Cardiol 55: A1.E2.
56. Patel M.R. Mahaffey K.W. Garg J. Pan G. Singer D.E. Hacke W. et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883–891.
57. Petersen P. Boysen G. Godtfredsen J. Andersen E.D. Andersen B. (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen Afasak Study. Lancet 1: 175–179.
58. Raghavan N. Frost C.E. Yu Z. He K. Zhang H. Humphreys W.G. et al. (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37: 74–81.
59. Roger V.L. Go A.S. Lloyd-Jones D.M. Adams R.J. Berry J.D. Brown T.M. et al. (2011) Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation 123: e18–e209.
60. Rohde L.E. de Assis M.C. Rabelo E.R. (2007) Dietary vitamin K intake and anticoagulation in elderly patients. Curr Opin Clin Nutr Metab Care 10: 1–5.
61. Ruff C.T. Giugliano R.P. Antman E.M. Crugnale S.E. Bocanegra T. Mercuri M. et al. (2010) Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 160: 635–641.
62. Ryan F. Byrne S. O'shea S. (2008) Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet based expert system. ASH Annual Meeting Abstracts 112: 879.
63. Ryan F. Byrne S. O'shea S. (2009) Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. J Thromb Haemost 7: 1284–1290.
64. Schurgers L.J. Shearer M.J. Hamulyak K. Stocklin E. Vermeer C. (2004) Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood 104: 2682–2689.
65. Singer D.E. Albers G.W. Dalen J.E. Fang M.C. Go A.S. Halperin J.L. et al. (2008) Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133: 546S–592S.
66. Sorensen S.V. Kansal A.R. Connolly S. Peng S. Linnehan J. Bradley-Kennedy C. et al. (2011) Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian Payer Perspective. Thromb Haemost 105, in press.
67. Stangier J. (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47: 285–295.
68. Stangier J. Rathgen K. Stahle H. Gansser D. Roth W. (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64: 292–303.
69. Stangier J. Rathgen K. Stahle H. Mazur D. (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49: 259–268.
70. Stangier J. Stahle H. Rathgen K. Fuhr R. (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47: 47–59.
71. Stroke Prevention in Atrial Fibrillation II Study Investigators (1994) Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343: 687–691.
72. Stroke Prevention in Atrial Fibrillation Study Investigators (1991) Stroke Prevention in Atrial Fibrillation Study. Final Results. Circulation 84: 527–539.
73. Taube J. Halsall D. Baglin T. (2000) Influence of cytochrome P-450 Cyp2c9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96: 1816–1819.
74. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators (1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 323: 1505–1511.
75. The European Atrial Fibrillation Trial Study Group (1995) Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 333: 5–10.
76. van Ryn J. Stangier J. Haertter S. Liesenfeld K.H. Wienen W. Feuring M. et al. (2010) Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103: 1116–1127.
77. Vecsler M. Loebstein R. Almog S. Kurnik D. Goldman B. Halkin H. et al. (2006) Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95: 205–211.
78. Veeger N.J.G.M. Piersma-Wichers M. Hillege H.L. Crijns H.J.G.M. van der Meer J. (2006) Early detection of patients with a poor response to vitamin K antagonists: the clinical impact of individual time within target range in patients with heart disease. J Thrombosis Haemostasis 4: 1625–1627.
79. Walenga J.M. Adiguzel C. (2010) Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 64: 956–967.
80. Wallentin L. Yusuf S. Ezekowitz M.D. Alings M. Flather M. Franzosi M.G. et al. (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376: 975–983.
81. Wang L. Zhang D. Raghavan N. Yao M. Ma L. Frost C.E. et al. (2010) In vitro assessment of metabolic drug–drug interaction potential of apixaban through cytochrome P 450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 38: 448–458.
82. Wann L.S. Curtis A.B. Ellenbogen K.A. Estes N.a.M. Ezekowitz M.D. Jackman W.M. et al. (2011) 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. Circulation:
83. Weinz C. Schwarz T. Kubitza D. Mueck W. Lang D. (2009) Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 37: 1056–1064.
84. Weitz J.I. Connolly S.J. Patel I. Salazar D. Rohatagi S. Mendell J. et al. (2010) Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 104: 633–641.
85. White H.D. Gruber M. Feyzi J. Kaatz S. Tse H.F. Husted S. et al. (2007) Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 167: 239–245.
86. Winkle R.A. Mead R.H. Engel G. Kong M.H. Patrawala R.A. (2011) The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol, in press.
87. Wolf P.A. Abbott R.D. Kannel W.B. (1991) Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 22: 983–988.
88. Zhang P. Huang W. Wang L. Bao L. Jia Z.J. Bauer S.M. et al. (2009) Discovery of betrixaban (Prt054021), N-(5-chloropyridin-2-Yl)-2-(4-(N, N-dimethylcarbamimidoyl)benzamido)-5-meth oxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett 19: 2179–2185.